Tiwari Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 04-01-2025
- Paid Up Capital ₹ 5.00 M
as on 04-01-2025
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 31.00 Cr
as on 04-01-2025
- Satisfied Charges ₹ 15.25 Cr
as on 04-01-2025
- Revenue 85.91%
(FY 2023)
- Profit 90.63%
(FY 2023)
- Ebitda 91.10%
(FY 2023)
- Net Worth 109.66%
(FY 2023)
- Total Assets 117.45%
(FY 2023)
About Tiwari Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹31.00 Cr. The company has closed loans amounting to ₹15.25 Cr, as per Ministry of Corporate Affairs (MCA) records.
Dilip Tiwari, Ajay Tiwari, and Dhirendra Tiwari serve as directors at the Company.
- CIN/LLPIN
U24304HP2018PTC007271
- Company No.
007271
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Dec 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Tiwari Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dilip Tiwari  | Director | 17-Dec-2018 | Current |
| Ajay Tiwari | Director | 17-Dec-2018 | Current |
| Dhirendra Tiwari | Director | 17-Dec-2018 | Current |
Financial Performance of Tiwari Pharma.
Tiwari Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 85.91% increase. The company also saw a substantial improvement in profitability, with a 90.63% increase in profit. The company's net worth Soared by an impressive increase of 109.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tiwari Pharma?
In 2023, Tiwari Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Sucantis Biotech Private LimitedActive 3 years 2 months
Dilip Tiwari and Dhirendra Tiwari are mutual person
Charges (Loans)
₹310.00 M
₹152.50 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 31.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Aug 2023 | Hdfc Bank Limited | ₹31.00 Cr | Open |
| 27 Feb 2023 | Axis Bank Limited | ₹13.00 Cr | Satisfied |
| 19 May 2020 | Others | ₹2.25 Cr | Satisfied |
How Many Employees Work at Tiwari Pharma?
Unlock and access historical data on people associated with Tiwari Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tiwari Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tiwari Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.